EGRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EGRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Eagle Pharmaceuticals's enterprise value is $115.2 Mil. Eagle Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $257.6 Mil. Therefore, Eagle Pharmaceuticals's EV-to-Revenue for today is 0.45.
The historical rank and industry rank for Eagle Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 11 years, the highest EV-to-Revenue of Eagle Pharmaceuticals was 31.86. The lowest was 0.45. And the median was 3.40.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-25), Eagle Pharmaceuticals's stock price is $4.24. Eagle Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $19.59. Therefore, Eagle Pharmaceuticals's PS Ratio for today is 0.22.
The historical data trend for Eagle Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eagle Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Sep13 | Sep14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 2.47 | 3.83 | 2.87 | 3.40 | 1.23 |
Eagle Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 2.23 | 1.32 | 1.23 | 1.60 | 1.21 |
For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Eagle Pharmaceuticals's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Eagle Pharmaceuticals's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 115.221 | / | 257.551 | |
= | 0.45 |
Eagle Pharmaceuticals's current Enterprise Value is $115.2 Mil.
Eagle Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $257.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eagle Pharmaceuticals (NAS:EGRX) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Eagle Pharmaceuticals's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 4.24 | / | 19.591 | |
= | 0.22 |
Eagle Pharmaceuticals's share price for today is $4.24.
Eagle Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Eagle Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott Tarriff | director, officer: President and CEO | 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430 |
Richard A. Edlin | director | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677 |
Michael Shawn Moran | officer: EVP, Chief Commercial Officer | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677 |
Luciana Borio | director | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677 |
Brian Joseph Cahill | officer: Chief Financial Officer | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677 |
Judith Ng-cashin | officer: Chief Medical Officer | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677 |
Hudson Executive Capital Lp | director | C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281 |
Hec Management Gp Llc | director | 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036 |
Jennifer K. Simpson | director | C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019 |
Douglas L Braunstein | director | HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022 |
Sander A Flaum | director | 630 PARK AVE, NEW YORK NY 10019 |
Pete A. Meyers | officer: Chief Financial Officer | C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355 |
David Pernock | director | 405 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Proquest Investments Iv, L.p. | 10 percent owner | 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109 |
Steven L. Krill | officer: Chief Scientific Officer | C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677 |
From GuruFocus
By PRNewswire • 01-23-2024
By PRNewswire • 12-27-2023
By PRNewswire • 12-19-2023
By PRNewswire • 12-29-2023
By PRNewswire • 01-02-2024
By PRNewswire • 12-18-2023
By PRNewswire • 01-18-2024
By PRNewswire • 01-11-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.